Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
76. |
ECCT/22/09/01 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Godfrey Allan Otieno Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
View |
77. |
ECCT/22/06/02 | Mitapivat - AG348-C-020 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. |
Principal Investigator(s) 1. Lucas Otieno Tina 2. Bernhards Ragama Ogutu 3. Prof Jessie N Githanga 4. Videlis N Nduba 5. Janet N/A Oyieko 6. Allan Godfrey Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Strathmore University Medical Centre (Nairobi City county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
View |
78. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
View |
79. |
ECCT/22/08/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Bernhards Ragama Ogutu 3. Fredrick Asirwa Chite 4. Videlis N Nduba Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Strathmore University Medical Centre (Nairobi City county) 3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 4. KEMRI/CRDR (Nairobi City county) 5. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
80. |
ECCT/22/04/01 | GBT Open Label inclacumab Ph3 An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Prof Jessie N Githanga 4. Videlis N Nduba Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital. (Nairobi City county) |
View |